Charles River Laboratories International, Inc.
CRL
$197.06
$3.211.66%
NYSE
| 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | 09/28/2024 | |
|---|---|---|---|---|---|
| Net Income | -119.42% | -115.18% | -104.48% | -95.32% | -10.77% |
| Total Depreciation and Amortization | 1.94% | 27.19% | 9.13% | 12.17% | 9.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,952.91% | 10,436.72% | 24,952.74% | 15,904.13% | -303.79% |
| Change in Net Operating Assets | -169.54% | 321.87% | 132.55% | 70.38% | 160.15% |
| Cash from Operations | -5.86% | 5.02% | 10.22% | 7.41% | 14.11% |
| Capital Expenditure | 12.67% | 20.52% | 26.70% | 26.86% | 28.42% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.00% | 100.00% | 96.21% | 97.19% | -199.20% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 80.35% | 121.43% | 92.01% | 86.68% | 66.43% |
| Cash from Investing | 52.71% | 61.29% | 57.37% | 56.48% | -45.28% |
| Total Debt Issued | -17.21% | 5.50% | 35.30% | 39.32% | 191.72% |
| Total Debt Repaid | 19.51% | 8.40% | -36.87% | -75.39% | -74.39% |
| Issuance of Common Stock | -97.35% | -95.19% | -93.28% | -6.72% | 7.36% |
| Repurchase of Common Stock | -202.63% | -2,401.87% | -3,094.12% | -393.38% | -393.03% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -33.21% | -90.40% | -442.10% | -273.21% | -409.79% |
| Cash from Financing | -59.54% | -100.67% | -629.96% | -544.20% | 23.27% |
| Foreign Exchange rate Adjustments | -83.32% | 334.72% | -89.77% | -317.23% | -14.49% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -105.26% | 113.45% | -182.38% | -282.38% | 250.60% |